These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 34801698)

  • 1. Adjuvant treatment of colon cancer with microsatellite instability - the state of the art.
    Oneda E; Zaniboni A
    Crit Rev Oncol Hematol; 2022 Jan; 169():103537. PubMed ID: 34801698
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognosis of microsatellite instability and/or mismatch repair deficiency stage III colon cancer patients after disease recurrence following adjuvant treatment: results of an ACCENT pooled analysis of seven studies.
    Taieb J; Shi Q; Pederson L; Alberts S; Wolmark N; Van Cutsem E; de Gramont A; Kerr R; Grothey A; Lonardi S; Yoshino T; Yothers G; Sinicrope FA; Zaanan A; André T
    Ann Oncol; 2019 Sep; 30(9):1466-1471. PubMed ID: 31268130
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical impact of microsatellite instability in colon cancer following adjuvant FOLFOX therapy.
    Kim ST; Lee J; Park SH; Park JO; Lim HY; Kang WK; Kim JY; Kim YH; Chang DK; Rhee PL; Kim DS; Yun H; Cho YB; Kim HC; Yun SH; Lee WY; Chun HK; Park YS
    Cancer Chemother Pharmacol; 2010 Sep; 66(4):659-67. PubMed ID: 20033812
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of DNA mismatch repair (MMR) status on oxaliplatin-based first-line chemotherapy as in recurrent or metastatic colon cancer.
    Kim ST; Lee J; Park SH; Park JO; Lim HY; Kang WK; Kim JY; Kim YH; Chang DK; Rhee PL; Kim DS; Yun H; Cho YB; Kim HC; Yun SH; Chun HK; Lee WY; Park YS
    Med Oncol; 2010 Dec; 27(4):1277-85. PubMed ID: 19949897
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Microsatellite instability and survival after adjuvant chemotherapy among stage II and III colon cancer patients: results from a population-based study.
    Alwers E; Jansen L; Bläker H; Kloor M; Tagscherer KE; Roth W; Boakye D; Herpel E; Grüllich C; Chang-Claude J; Brenner H; Hoffmeister M
    Mol Oncol; 2020 Feb; 14(2):363-372. PubMed ID: 31816156
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Is Adjuvant Chemotherapy Necessary for Patients with Deficient Mismatch Repair Gastric Cancer?-Autophagy Inhibition Matches the Mismatched.
    Tsai CY; Lin TA; Huang SC; Hsu JT; Yeh CN; Chen TC; Chiu CT; Chen JS; Yeh TS
    Oncologist; 2020 Jul; 25(7):e1021-e1030. PubMed ID: 32058649
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Impact of Mismatch Repair Status in Colorectal Cancer on the Decision to Treat With Adjuvant Chemotherapy: An Australian Population-Based Multicenter Study.
    He EY; Hawkins NJ; Mak G; Roncolato F; Goldstein D; Liauw W; Clingan P; Chin M; Ward RL
    Oncologist; 2016 May; 21(5):618-25. PubMed ID: 27009937
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Microsatellite instability testing and its role in the management of colorectal cancer.
    Kawakami H; Zaanan A; Sinicrope FA
    Curr Treat Options Oncol; 2015 Jul; 16(7):30. PubMed ID: 26031544
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Predictive and prognostic value of MSI phenotype in adjuvant colon cancer: Who and how to treat?].
    Zaanan A; Taieb J
    Bull Cancer; 2019 Feb; 106(2):129-136. PubMed ID: 30527814
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Survival benefit with adjuvant chemotherapy in stage III microsatellite-high/deficient mismatch repair colon cancer: a systematic review and meta-analysis.
    Tomasello G; Ghidini M; Galassi B; Grossi F; Luciani A; Petrelli F
    Sci Rep; 2022 Jan; 12(1):1055. PubMed ID: 35058539
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Microsatellite instability is a favorable prognostic indicator in patients with colorectal cancer receiving chemotherapy.
    Hemminki A; Mecklin JP; Järvinen H; Aaltonen LA; Joensuu H
    Gastroenterology; 2000 Oct; 119(4):921-8. PubMed ID: 11040179
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rationale and design of the POLEM trial: avelumab plus fluoropyrimidine-based chemotherapy as adjuvant treatment for stage III mismatch repair deficient or POLE exonuclease domain mutant colon cancer: a phase III randomised study.
    Lau D; Kalaitzaki E; Church DN; Pandha H; Tomlinson I; Annels N; Gerlinger M; Sclafani F; Smith G; Begum R; Crux R; Gillbanks A; Wordsworth S; Chau I; Starling N; Cunningham D; Dhillon T
    ESMO Open; 2020 Feb; 5(1):. PubMed ID: 32079623
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Multi-cohort Study of the Prognostic Significance of Microsatellite Instability or Mismatch Repair Status after Recurrence of Resectable Gastric Cancer.
    An JY; Choi YY; Lee J; Hyung WJ; Kim KM; Noh SH; Choi MG; Cheong JH
    Cancer Res Treat; 2020 Oct; 52(4):1153-1161. PubMed ID: 32599987
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Microsatellite Instability in Patients With Stage III Colon Cancer Receiving Fluoropyrimidine With or Without Oxaliplatin: An ACCENT Pooled Analysis of 12 Adjuvant Trials.
    Cohen R; Taieb J; Fiskum J; Yothers G; Goldberg R; Yoshino T; Alberts S; Allegra C; de Gramont A; Seitz JF; O'Connell M; Haller D; Wolmark N; Erlichman C; Zaniboni A; Lonardi S; Kerr R; Grothey A; Sinicrope FA; André T; Shi Q
    J Clin Oncol; 2021 Feb; 39(6):642-651. PubMed ID: 33356421
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical Significance and Prognostic Relevance of Microsatellite Instability in Sporadic Colorectal Cancer Patients.
    Copija A; Waniczek D; Witkoś A; Walkiewicz K; Nowakowska-Zajdel E
    Int J Mol Sci; 2017 Jan; 18(1):. PubMed ID: 28067827
    [TBL] [Abstract][Full Text] [Related]  

  • 16. DNA mismatch repair status and colon cancer recurrence and survival in clinical trials of 5-fluorouracil-based adjuvant therapy.
    Sinicrope FA; Foster NR; Thibodeau SN; Marsoni S; Monges G; Labianca R; Kim GP; Yothers G; Allegra C; Moore MJ; Gallinger S; Sargent DJ
    J Natl Cancer Inst; 2011 Jun; 103(11):863-75. PubMed ID: 21597022
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Microsatellite instability predicts improved response to adjuvant therapy with irinotecan, fluorouracil, and leucovorin in stage III colon cancer: Cancer and Leukemia Group B Protocol 89803.
    Bertagnolli MM; Niedzwiecki D; Compton CC; Hahn HP; Hall M; Damas B; Jewell SD; Mayer RJ; Goldberg RM; Saltz LB; Warren RS; Redston M
    J Clin Oncol; 2009 Apr; 27(11):1814-21. PubMed ID: 19273709
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ERCC1, defective mismatch repair status as predictive biomarkers of survival for stage III colon cancer patients receiving oxaliplatin-based adjuvant chemotherapy.
    Li P; Fang YJ; Li F; Ou QJ; Chen G; Ma G
    Br J Cancer; 2013 Apr; 108(6):1238-44. PubMed ID: 23481186
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Microsatellite instability in colorectal cancer: overview of its clinical significance and novel perspectives.
    Battaglin F; Naseem M; Lenz HJ; Salem ME
    Clin Adv Hematol Oncol; 2018 Nov; 16(11):735-745. PubMed ID: 30543589
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Microsatellite Instability was not Associated with Survival in Stage III Colon Cancer Treated with Adjuvant Chemotherapy of Oxaliplatin and Infusional 5-Fluorouracil and Leucovorin (FOLFOX).
    Kim JE; Hong YS; Kim HJ; Kim KP; Kim SY; Lim SB; Park IJ; Kim CW; Yoon YS; Yu CS; Kim JC; Kim JH; Kim TW
    Ann Surg Oncol; 2017 May; 24(5):1289-1294. PubMed ID: 27853901
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.